Online inquiry

IVTScrip™ mRNA-Anti-TNF, TNFR55-Ig1(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ15320MR)

This product GTTS-WQ15320MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets TNF gene. The antibody can be applied in Allergic asthma, Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000594.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7124
UniProt ID P01375
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNF, TNFR55-Ig1(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ15320MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7283MR IVTScrip™ mRNA-Anti-CSF1R, FPA-008(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA FPA-008
GTTS-WQ6594MR IVTScrip™ mRNA-Anti-DPEP3, DC-1728001(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA DC-1728001
GTTS-WQ13742MR IVTScrip™ mRNA-Anti-ANGPTL3, REGN 1500(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA REGN 1500
GTTS-WQ6821MR IVTScrip™ mRNA-Anti-STEAP1, DSTP-3086S(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA DSTP-3086S
GTTS-WQ5434MR IVTScrip™ mRNA-Anti-CD74, CD74-DOX (ADC)(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CD74-DOX (ADC)
GTTS-WQ4650MR IVTScrip™ mRNA-Anti-FGFR1, BMS-986036(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BMS-986036
GTTS-WQ10582MR IVTScrip™ mRNA-Anti-ANGPT2, LY-3127804(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA LY-3127804
GTTS-WQ6378MR IVTScrip™ mRNA-Anti-Factor IX substitute, CSL654(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CSL654
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW